EUCTR2019-002073-56-BE进行中（未招募）1 期
A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects with Nonalcoholic Steatohepatitis (NASH) with Open-Label Part to Evaluate the Safety, PK and Treatment Response Kinetics of Aramchol.The ARMOR Study
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 2,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •The inclusion criteria for the Open-Label Part are the same as those of the Randomized, Double-Blind, Placebo-Controlled Part with the
- •exception of fibrosis stage (the Open-Label Part allows enrollment of subjects with fibrosis stage 1), weight (the Open-Label Part allows
- •enrollment of subjects who are not overweight) and Type diabetes mellitus (the Open-Label Part allows enrollment of subjects who are not prediabetic or subjects who do not have type 2 diabetes mellitus).
- •1. Male or female age 18 to 75 years (inclusive at first Screening visit)
- •2. Histological confirmation of NASH on a diagnostic liver biopsy by central reading of the slides
- •Open-Label Part: biopsy obtained within 9 months prior to randomization or during the screening period.
- •Randomized, Double-Blind, Placebo-Controlled Part: biopsy obtained within 6 months prior to randomization or during the screening period.
- •3. Total NAS Score 4 or more with at least 1 in each component of the NAS Score (steatosis =1 AND inflammation =1 AND ballooning =1)
- •4. Fibrosis Stage must be 2 or 3
- •Open-Label Part only: 30 subjects with fibrosis stage 1 may be included
- •5. Subjects who have had a biopsy more than 3 months before randomization should have stable weights between the time of the biopsy and screening. Stable weight is defined as no more than a 5 percent change
- •6. Body mass index (BMI)
- •Open-Label Part: = 40 kg/m2
- •Randomized, Double-Blind, Placebo-Controlled Part: between 25kg/m2 and 40 kg/m2
- •7. The subject made at least one attempt of dietary and/or lifestyle change guided by professional counseling in the past and no new attempts to make dietary and/or lifestyle changes have been initiated within the 3 months prior to screening or is actively being sought now
- •8. Randomized, Double-Blind, Placebo-Controlled Part only: Type 2 diabetes mellitus or prediabetes: Type 2 diabetes diagnosis must be established and documented prior to screening. For prediabetes, unless pharmacologically treated, the diagnosis should be verified by screening results (by central lab) according to the American Diabetes Association criteria, which requires at least one of the following 3 criteria:
- •Fasting Plasma Glucose 100 - 125 mg/dL (5.6 - 6.9 mmol/L)
- •Post-load glucose (2hPG) following 75g oral glucose tolerance test
- •(OGTT) 140 - 199 mg/dL (7.8 -11.0 mmol/L)
- •Glycosylated Hemoglobin (HbA1c) 5.7% - 6.4%
- •9. For subjects with type 2 diabetes, glycemia must be controlled (HbA1c = 9%)
- •10. Negative blood pregnancy test at study entry for females of childbearing potential confirmed by central laboratory
- •11. Females of childbearing potential must practice a highly effective method of contraception at least 1 month prior to randomization, throughout the study period and for 1 month after treatment discontinuation
- •- A woman is considered of childbearing potential if fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.
- •- Highly effective methods are defined as those that can achieve a failure rate of less than 1% per year when used consistently and correctly. Such methods, in accordance with the recommendations of the Clinical Trial Facilitation Group (CTFG) Working Group on Contraception include:
- •Hormonal contraception associated with inhibition of ovulation, intr
排除标准
- •All exclusion criteria for the Open-Label Part are the same as those of the Randomized, Double-Blind, Placebo-Controlled Part.
- •1. Histologically documented liver cirrhosis (fibrosis stage 4)
- •2. Inability or unwillingness to undergo a liver biopsy
- •3. Abnormal synthetic liver function
- •Albumin below the lower limit of the normal range
- •International Normalized Ratio (INR) = 1.3;
- •Total bilirubin = 1.3 mg/dL (22.2 µmol/L); subjects with a documented history of Gilbert's syndrome can be enrolled if the direct bilirubin is within normal reference range
- •4. ALT or AST >5× upper limit of normal (ULN); according to central laboratory
- •5. Platelet count < 150,000mm3
- •6. Alkaline phosphatase =2× ULN
- •7. Known or suspected hepatocellular carcinoma (HCC)
- •8. Model for End-Stage Liver Disease (MELD) score > 12 using OPTN formula
- •9. Prior history of/or planned liver transplantation
- •10. Prior history or presence of decompensated liver disease
- •11. Current or past evidence of portal hypertension (e.g., low platelet counts, esophageal varices, ascites, history of hepatic encephalopathy, splenomegaly)
- •12. Other (acute or chronic) coexisting liver disease based on medical history and/or centralized review of liver histology including:
- •Subjects positive for hepatitis C antibodies unless sustained virologic response (SVR) is documented at least 3 years prior to screening and
- •confirmed at screening by central laboratory
- •Subjects positive for Hepatitis B surface antigen (HBsAg)
- •Primary biliary cholangitis (PBC)
- •Primary sclerosing cholangitis (PSC)
- •Genetic hemochromatosis
- •Wilson's disease
- •Alpha 1 antitrypsin deficiency
- •Autoimmune hepatitis
- •Alcoholic liver disease
- •Drug-induced liver disease
- •13. Known alcohol and/or any other drug abuse or dependence in the last five years
- •Daily alcohol intake will be an exclusion if >20 g/day for women and >30 g/day for men (on average per day), as per medical history
- •14. Human immunodeficiency virus HIV infection (either known or diagnosed during Screening blood tests)
- •15. Known familial (i.e., genetic) hypertriglyceridemia or familial (i.e., genetic) hypercholesterolemia
- •16. Diabetes Mellitus other than type 2 (type 1, endocrinopathy, genetic syndromes etc.)
- •17. Weight loss of more than 5% within 3 months prior to screening
- •18. History of bariatric surgery within 5 years of liver biopsy or planned surgery for weight reduction
- •19. Treatment with drugs that may cause NAFLD within 12 months prior to the biopsy (e.g. valproic acid, tamoxifen, methotrexate, amiodarone, chronic treatment with corticosteroids, high dose estrogen and tetracycline)
- •20. Treatment with Vitamin E unless started at least 12 months prior to biopsy, with stable dose in the 6 months prior to biopsy
- •Subjects that stopped treatment less than 6 months prior to biopsy should be excluded
- •21. Treatment with GLP-1 receptor agonists or thiazolidinediones (TZDs) unless started at least 12 months prior to biopsy, with stable dose in the
- •6 months prior to biopsy
- •Subjects that stopped treatment less than 6 months prior to biopsy should be excluded
- •22. Treatment with SGLT-2 inhibitors, metformin, sulfonylurea, insulin, and DPP-4 inhibitors unless the prescribed dose has been stable for 3 months prior to screening
- •23. Treatment with fibrates and statins unless the prescribed dose has been stable for 3 months prior to screening
- •24. Previous treatment with polyunsaturated fatty acid, ursodeoxycholic acid or fish oil unless stable for at least 6 month
研究者
相似试验
进行中（未招募）
3 期
A Phase 3, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Induction and Maintenance Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Eosinophilic EsophagitisEosinophilic esophagitisJPRN-jRCT2051200140Inoue Tomoyoshi33
已完成
3 期
A Phase 3, Multicenter, Multinational, Randomized, Open-Label, Parallel-Arm Study of Avelumab* (MSB0010718C) plus Best Supportive Care Versus Best Supportive Care Alone as a Maintenance Treatment in Patients with Locally Advanced or Metastatic Urothelial Cancer whose Disease did not Progress after Completion of First-Line Platinum-Containing ChemotherapyNL-OMON55699Pfizer20
进行中（未招募）
3 期
clinical trial in patient with locally advance or metastatic cancer of the urinary tractCTRI/2017/01/007696Pfizer Inc6
进行中（未招募）
1 期
A study to look at the efficacy and safety of ALN TTRSC in patients with an inherited condition that causes certain protein molecules to deposit in the heartTrasthyretin (TTR) mediated familial amyloidotic cardiomyopathy (FAC)MedDRA version: 20.0Level: PTClassification code 10016202Term: Familial amyloidosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2014-003835-20-ITALNYLAM PHARMACEUTICALS, INC.206
未知
3 期
A Phase 3 Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Comparative Efficacy and Safety Study of D961H (20 mg Once Daily) Versus Placebo for Prevention of Gastric and/or Duodenal Ulcers Associated With Continuous Low-dose Aspirin (LDA) UsePatient diagnosed as a chronic condition (angina pectoris, myocardial infarction and ischemic cerebrovascular disorder, etc., requiring prevention of thrombosis or embolism) that is taking the prescribed LDA continuouslyJPRN-jRCT2080221059AstraZeneca